Kyverna Therapeutics reports positive one-year KYSA-8 data for miv-cel in stiff person syndrome

Kyverna flagged new one-year results from its KYSA-8 registrational trial of miv-cel in stiff person syndrome, to be presented at MSToronto2026 on Oct. 21, 2026. Updated Phase 1 investigator-initiated progressive multiple sclerosis findings will be presented Oct. 23, 2026. Management said it is working to complete a BLA in its initial indication this quarter.